These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2218198)

  • 1. Estimating benefits of screening from observational cohort studies.
    Flanders WD; Longini IM
    Stat Med; 1990 Aug; 9(8):969-80. PubMed ID: 2218198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case-control evaluation of breast cancer screening efficacy.
    Friedman DR; Dubin N
    Am J Epidemiol; 1991 May; 133(10):974-84. PubMed ID: 2035508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias.
    Lawrence G; Wallis M; Allgood P; Nagtegaal ID; Warwick J; Cafferty FH; Houssami N; Kearins O; Tappenden N; O'Sullivan E; Duffy SW
    Breast Cancer Res Treat; 2009 Jul; 116(1):179-85. PubMed ID: 18622697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous tumour growth models, lead time estimation and length bias in breast cancer screening studies.
    Abrahamsson L; Isheden G; Czene K; Humphreys K
    Stat Methods Med Res; 2020 Feb; 29(2):374-395. PubMed ID: 30854935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dentification and correction of the lead-time bias and length bias in cancer screening studies].
    Yang Z; Zhou JC; Chen R; Wei WW
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Nov; 53(11):1183-1187. PubMed ID: 31683411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival.
    Duffy SW; Nagtegaal ID; Wallis M; Cafferty FH; Houssami N; Warwick J; Allgood PC; Kearins O; Tappenden N; O'Sullivan E; Lawrence G
    Am J Epidemiol; 2008 Jul; 168(1):98-104. PubMed ID: 18504245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restriction as a method for reducing bias in the estimation of direct effects.
    Joffe MM; Colditz GA
    Stat Med; 1998 Oct; 17(19):2233-49. PubMed ID: 9802181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing the effects of lead-time bias, length bias and over-detection in evaluating screening mammography: a censored bivariate data approach.
    Mahnken JD; Chan W; Freeman DH; Freeman JL
    Stat Methods Med Res; 2008 Dec; 17(6):643-63. PubMed ID: 18445697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The yield of breast cancer screening: the importance of observational data and the problems of bias].
    Giard RW
    Ned Tijdschr Geneeskd; 2004 Feb; 148(8):352-5. PubMed ID: 15032087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of lead-time bias in estimates of relative survival for breast cancer.
    Andersson TM; Rutherford MJ; Humphreys K
    Cancer Epidemiol; 2017 Feb; 46():50-56. PubMed ID: 28027488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of design and bias issues in case-control studies of cancer screening using microsimulation.
    Connor RJ; Boer R; Prorok PC; Weed DL
    Am J Epidemiol; 2000 May; 151(10):991-8. PubMed ID: 10853638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating cancer screening programs using survival analysis.
    Vratanar B; Pohar Perme M
    Biom J; 2023 Oct; 65(7):e2200344. PubMed ID: 37278228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case-control evaluation of the effect of breast cancer screening in the United Kingdom trial of early detection of breast cancer.
    Moss SM; Summerley ME; Thomas BT; Ellman R; Chamberlain JO
    J Epidemiol Community Health; 1992 Aug; 46(4):362-4. PubMed ID: 1431707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A data-analytic approach for estimating lead time and screening benefit based on survival curves in randomized cancer screening trials.
    Kafadar K; Prorok PC
    Stat Med; 1994 Mar 15-Apr 15; 13(5-7):569-86. PubMed ID: 8023036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiologic approach for cancer screening. Problems in design and analysis of trials.
    Prorok PC
    Am J Pediatr Hematol Oncol; 1992 May; 14(2):117-28. PubMed ID: 1530116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the age to begin periodic breast cancer screening using data from a few regularly scheduled screenings.
    Baker SG
    Biometrics; 1998 Dec; 54(4):1569-78. PubMed ID: 9883553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the benefits of mammography screening: the impact of study design.
    Olsen AH; Njor SH; Lynge E
    Epidemiology; 2007 Jul; 18(4):487-92. PubMed ID: 17486020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Instrumental variables and inverse probability weighting for causal inference from longitudinal observational studies.
    Hogan JW; Lancaster T
    Stat Methods Med Res; 2004 Feb; 13(1):17-48. PubMed ID: 14746439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bias in case-control studies of screening effectiveness.
    Hosek RS; Flanders WD; Sasco AJ
    Am J Epidemiol; 1996 Jan; 143(2):193-201. PubMed ID: 8546121
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.